Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties with a Hold Rating
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
Moderna's mRNA Technology Looks Undervalued Despite Lower Covid Vaccine Demand
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.
Billed as nonaddictive, new pain pill could soon win FDA approval
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
My 3 Highest-Conviction Growth Stocks to Buy in 2025
However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...